An algorithm for guiding clinical judgments about the futility of anti-VEGF treatment of neovascular age-related macular degeneration (nvAMD) has importance from clinical, ethical, and legal perspectives and would be a valuable decision-making tool for retina specialists and payors, according to David T. Wong, MD.
There are a number of ongoing clinical trials investigating treatments for dry age-related macular degeneration (AMD). These modalities include medications that are already in use for other indications and investigational agents representing various novel mechanisms of action.
To evaluate patients with uveitis, a tailored multimodal imaging approach can be very helpful both in the clinic and in clinical trials. With selective imaging, you can integrate and correlate the data from different images for a more conclusive diagnosis.
Tocilizumab, a recombinant humanized, antihuman monoclonal antibody, can be effective in improving visual acuity and reducing vitreous haze in patients with noninfectious uveitis, according to a recent study.
JIA-associated uveitis is a challenging inflammatory condition in the pediatric population. Adalimumab was found to be effective and safe in reducing ocular imflammation within 2 months and well tolerated over 12 months in JIA-associated uveitis.
Results from the Study Assessing double-masKed Uveitis tREAtrement (SAKURA) program support the efficacy and safety of intravitreal sirolimus 440 mcg (Opsiria, Santen) for treating noninfectious uveitis of the posterior segment, said Pauline T. Merrill, MD.
Cataract surgery in patients with coexisting uveitis is more challenging than managing either condition alone. Surgeons must answer a different set of questions and consider alternative management strategies, said Debra A. Goldstein, MD, FRSC, professor of ophthalmology and director of the Uveitis Service, Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago.
New technology has been paired with the time-tested technique of direct ophthalmoscopy to create a portable, retinal imaging system (D-Eye, D-Eye S.r.l.) that utilizes a small optical device magnetically attached to a smartphone.
The scientific community knows that vascular endothelial growth factor (VEGF) causes increased, vascular permeability, resulting in diabetic macular edema (DME) in the ischemic retina, but how to stop the VEGF drive remains the challenge.